Affinity Asset Advisors
JSPR icon

Affinity Asset Advisors’s Jasper Therapeutics JSPR Stock Holding History

Affinity Asset Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.07M Buy
+61,667
New +$1.24M 0.04% 116
2023
Q3 		– Sell
-1,590
Closed -$653K – 89
2023
Q2 		$653K Hold
1,590
– – 0.23% 60
2023
Q1 		$863K Buy
+1,590
New +$882K 0.28% 59

Other funds holding JSPR

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Carlyle Group
Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $18B AUM 27.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Landscape Capital Management
Landscape Capital Management Englewood, New Jersey $1.34B AUM 18.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Affinity Asset Advisors's JSPR Position: Q3 2026 in Review

Affinity Asset Advisors opened a new position in Jasper Therapeutics (JSPR) in Q3 2026: 61,667 shares worth $1.07M. The stake represents 0.04% of the portfolio and ranks #116 among its holdings. This is a return to the name: Affinity Asset Advisors previously reported a position in JSPR as recently as Q2 2023.

Affinity Asset Advisors first reported a position in JSPR in Q1 2023 and has held it in 3 quarters since. 26 funds tracked by Wall St. Rank hold JSPR as of Q3 2026.

  • Affinity Asset Advisors held 61,667 shares of Jasper Therapeutics worth $1.07M as of Q3 2026.
  • Jasper Therapeutics was a new Affinity Asset Advisors position in Q3 2026.
  • Jasper Therapeutics made up 0.04% of Affinity Asset Advisors's portfolio in Q3 2026, its #116 holding.
  • Affinity Asset Advisors first reported a position in Jasper Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • 26 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.